Jazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of...
Monday, December 10, 2012, 7:35 PM ETJazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of patients treated with Erwinaze for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The trial, which was presented at the American Society of Hematology Annual Meeting and Exposition, includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the drug's known safety profile.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles